TenX Keane Acquisition Right
TENKR
NASDAQ0.48
USD
-0.03
- -
CIK
0001851484
ISIN
KYG8708L1124
Return %
Stock
S&P500
1Y
149.51
15.98
3Y
269.23
62.25
5Y
269.23
67.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Xiaofeng Yuan
- Sector
- Financial Services
- Industry
- Financial - Conglomerates
- Address
- CIK
- 0001851484
- Similar Companies
- Business
- TenX Keane Acquisition Right (TENKR) represents the rights of TenX Keane Acquisition, a blank check company, or special purpose acquisition company (SPAC), incorporated as an exempted company in the Cayman Islands in 2022 and headquartered in New York, that seeks to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. TenX Keane Acquisition's securities, including ordinary shares (TENK), units (TENKU), and rights (TENKR), trade on the Nasdaq Global Market. The company does not currently conduct active operations or generate revenue prior to completing its initial business combination, with proceeds from its 2022 initial public offering of 6.6 million units at $10.00 per unit held in trust for such purpose. In August 2024, TenX Keane Acquisition completed its business combination through the merger with a wholly owned oncology subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), forming Citius Oncology, Inc. (Nasdaq: CTOR), a publicly traded biopharmaceutical platform focused on developing and commercializing novel targeted oncology therapies, including the recently FDA-approved LYMPHIR for relapsed or refractory cutaneous T-cell lymphoma. Pursuant to the merger agreement announced in October 2023, Citius Pharmaceuticals holds approximately 90% ownership of Citius Oncology, which assumed existing options and began trading under new symbols, while TenX Keane's legacy rights (TENKR) were impacted by Nasdaq trading suspensions effective August 13, 2024. This transaction provides Citius Oncology enhanced access to public equity markets to support LYMPHIR commercialization and pursue additional oncology assets.